Subscribe to our Newsletters !!
The delicate, slend
Fremont, CA, September 20, 2021 — Biotium, a lea
A phase one trial of a multivariant COVID-19 vacci
September 20, 2021 –– Takara Bio Europe AB (TB
Dr Reddy's Laboratories was granted approval by th
BioChromato report how their ionRocket sample prep
Flow cytometry is a technology that provides rapid
Mumbai, India, June 23, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).
Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana®.
Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. According to IQVIA (IMS Health), Brovana® had US sales of approximately $438M for the 12-month period ending April 2021.
The product is available for shipping immediately.